AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20507969
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment - 4 weeks, 60 breaths once daily at approximately 15% of MIP
Trial: 18699898
Drug: Ephedrine 70
RxNorm normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 70 microg.kg(‐1) administered at 4 min before rocuronium
Trial: 18699898
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered at 4 min before rocuronium (Control)
Trial: 18699898
Drug: Ephedrine 70
RxNorm normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 70 microg.kg(‐1) administered at 30 s before rocuronium (Late)
Trial: 9129896
Drug: Digoxin 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 1.25 mg
Trial: 1901187
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms vaccine
Trial: 9251847
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms vaccine
Trial: 1901187
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms vaccine
Trial: 7092002
Drug: Tetracycline, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline, 500 mg by mouth every 6 hours for 1 week
Trial: 30798020
Drug: Ambulatory assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory assessment methods for treatment adherence and substance use data collection
Trial: 30798020
Drug: Eligibility criteria
RxNorm normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligibility criteria verification, treatment adherence monitoring, and remote assessment of substance use and biomarkers
Trial: 24560581
Drug: Alcohol (breath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (breath alcohol concentration of .6 g/kg)
Trial: 22038192
Drug: Phonophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis with non-steroid anti-inflammatory drug (PNSAI)
Trial: 19106767
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release (GXR) 1-4 mg doses
Trial: 9541371
Drug: Oral feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feedback (University 1)
Trial: 9541371
Drug: Oral feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feedback (University 2)
Trial: 22617128
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (ZOL) 4 mg every 3 weeks for 1 year
Trial: 17805038
Drug: Erwinia asparaginase
RxNorm normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erwinia asparaginase (ASP) substituted at the same dose and schedule due to allergic reaction to E. coli ASP
Trial: 17805038
Drug: Intramuscular E.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular E. coli ASP (6000 U/m2x6) followed by intensive weekly intramuscular E. coli ASP (25,000 U/m2/wkx24)
Trial: 9735610
Drug: Systemic-behavioral family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic-behavioral family therapy
Trial: 30580203
Drug: Manual-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-only treatment program for caffeine cessation and reduction over a period of 6 weeks; no counseling or additional support.
Trial: 30580203
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment group (manual-only treatment).
Trial: 30580203
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment group (treatment delayed by 7 weeks).
Trial: 26115748
Drug: Intravenous adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine triphosphate (ATP) administered after successful PVI to reveal dormant conduction (DC) sites.
Trial: 21997315
Drug: Rimonabant (10-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (10-week treatment)
Trial: 23389382
Drug: Placebo (10-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10-week treatment)
Trial: 16959685
Drug: Combined systemic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined systemic and local Pycnogenol treatment
Trial: 16959685
Drug: Oral Pycnogenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Pycnogenol only
Trial: 20943066
Drug: Medications only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications only (control group)
Trial: 14976608
Drug: Fosmidomycin-clindamycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin-clindamycin (30 and 5 mg/kg body weight every 12 h for 5 days)
Trial: 14976608
Drug: Fosmidomycin alone
RxNorm normalized name: Fosmidomycin
DrugBank: Fosmidomycin (DB02948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin alone (30 mg/kg body weight every 12 h for 5 days)
Trial: 14976608
Drug: Clindamycin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin alone (5 mg/kg body weight every 12 h for 5 days)
Trial: 9469525
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg subcutaneous before surgery and 30 ml saline infiltrated into the wound at skin incision)
Trial: 9469525
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 ml into an arm before surgery) and Morphine (10 mg in 30 ml saline into the wound at skin incision)
Trial: 9469525
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of i.v. morphine
Trial: 2907519
Drug: Propranolol (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40, 80 mg twice daily)
Trial: 2907519
Drug: Ketanserin (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20, 40 mg twice daily)
Trial: 2907519
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Propranolol added to Ketanserin)
Trial: 2907519
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Ketanserin added to Propranolol)
Trial: 25450868
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of sclerosant through an occluding balloon catheter (OB technique)
Trial: 25450868
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of sclerosant through a diagnostic catheter (free catheter technique)
Trial: 21692281
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) combined with psychological interference (combined therapy group)
Trial: 21692281
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group (EA + psychotherapy)
Trial: 11979157
Drug: Extensive multidisciplinary
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extensive multidisciplinary treatment program
Trial: 11979157
Drug: Light multidisciplinary
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light multidisciplinary treatment program
Trial: 16310718
Drug: Treatment-as-usual initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual initiated by a general practitioner
Trial: 15110919
Drug: Newborns with
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newborns with parental atopy and elevated cord IgE (> or = 0.5 kU/l)
Trial: 9311710
Drug: Neoral (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral (10 mg/kg/day)
Trial: 9311710
Drug: Sandimmune (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune (10 mg/kg/day)
Trial: 8141713
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) and subcutaneous heparin (n = 9796)
Trial: 8141713
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) and intravenous heparin (n = 10,377)
Trial: 8141713
Drug: Accelerated tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated tissue plasminogen activator (t‐PA) and intravenous heparin (n = 10,344)
Trial: 27084867
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel along with physiotherapy
Trial: 27084867
Drug: Antioxidant capsules
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant capsules along with physiotherapy
Trial: 15946410
Drug: GLU+FRUC (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU+FRUC (1.2 g/min glucose + 1.2 g/min fructose)
Trial: 15946410
Drug: GLU (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU (1.2 g/min glucose)
Trial: 12680333
Drug: Intrameatal application
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrameatal application of low dosage alprostadil (PGE1) cream (300 mcg)
Trial: 10525926
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (therapy only in case of occurrence of atrial fibrillation)
Trial: 20626055
Drug: External Qigong
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Qigong Treatment (EQT)
Trial: 17405567
Drug: New drug-elution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drug-elution stents
Trial: 10381908
Drug: rNV VLPs
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rNV VLPs (250 micrograms) administered orally on days 1 and 21
Trial: 10381908
Drug: rNV VLPs
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rNV VLPs (250 micrograms) administered orally
Trial: 8917873
Drug: Hospital dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital dosing
Trial: 6123675
Drug: Metkephamid acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metkephamid acetate 70 mg
Trial: 6123675
Drug: Pethidine hydrochloride
RxNorm normalized name: Pethidine hydrochloride
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine hydrochloride 100 mg
Trial: 28694884
Drug: Local steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid injections
Trial: 28694884
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (exercise + local steroid injections)
Trial: 25565079
Drug: Box-Cox transformation
RxNorm normalized name: ALLERGENIC EXTRACT, BOX ELDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Box-Cox transformation method for treatment effect estimation
Trial: 20872043
Drug: Sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib malate at a daily dose of 37.5 mg until progression or unacceptable toxicity
Trial: 20872043
Drug: Sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib malate at a daily dose of 37.5 mg
Trial: 10945486
Drug: Irinotecan single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan single-agent after 5-FU failure
Trial: 9294406
Drug: Dysport (muscle-relaxant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport (muscle-relaxant doses)
Trial: 31516033
Drug: D/C/F/TAF (800/150/200/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/C/F/TAF (800/150/200/10 mg)
Trial: 30899941
Drug: Twin-block appliance
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twin-block appliance treatment in experimental group (21 patients)
Trial: 21182783
Drug: Levosimendan 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 0.2 μg·kg(‐1)·min(‐1)
Trial: 21182783
Drug: Dobutamine 5
RxNorm normalized name: dobutamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine 5 μg·kg(‐1)·min(‐1) (control)
Trial: 16621906
Drug: Gonadotropin suppression
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin suppression by GnRH antagonist (cetrorelix) with testosterone and additional administration of the gestogen desogestrel (CTD group)
Trial: 16621906
Drug: Gonadotropin suppression
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin suppression by GnRH antagonist (cetrorelix) with testosterone (CT group)
Trial: 8640161
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and colony-stimulating factors (group I)
Trial: 8640161
Drug: G‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF alone (18 patients)
Trial: 26715196
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion (30 ml/kg whole blood)
Trial: 26715196
Drug: Conservative transfusion
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative transfusion (20 ml/kg)
Trial: 24384959
Drug: ATP‐TCA directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP‐TCA directed chemotherapy regimen (specific regimens include paclitaxel+carboplatin, paclitaxel+oxaliplatin, bleomycin+ifosfamide+cisplatin, bleomycin+vincristine+cisplatin, fluorouracil+cisplatin, gemcitabine+cisplatin)
Trial: 24384959
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group chemotherapy regimen confirmed by clinical experience
Trial: 20473991
Drug: Soybean plus
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean plus fish oil emulsion (1.0 and 0.2 g per kg per day respectively)
Trial: 20473991
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil alone (1.2 g per kg bodyweight per day; control group)
Trial: 12610030
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) plus free blood testing strips
Trial: 7040158
Drug: Bethanechol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol and antacid
Trial: 7040158
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and antacid
Trial: 28274246
Drug: TNF‐α production
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α production less than 250 pg/ml after lipopolysaccharide stimulation on day 3
Trial: 27208415
Drug: Trehalose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose (100 g/day)
Trial: 23032742
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with modified HLA class I tumor peptides (Melan‐A/MART‐1([27L]), gp100([210M]), NY‐ESO‐1([165V]), and Survivin([97M])) emulsified in Montanide ISA51, injected subcutaneously with cyclophosphamide (300 mg/m(2)) and low‐dose IL‐2 (3 × 10(6) IU).
Trial: 19541691
Drug: Collagen-gentamicin sponges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-gentamicin sponges applied between sternal halves in addition to routine intravenous antibiotics
Trial: 19541691
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous study with intravenous prophylaxis only)
Trial: 17641452
Drug: Extra-curricular aerobic
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-curricular aerobic dynamic physical activity (swimming, water games, folk dance, soccer) for 35 weeks, 45 min of physical classes plus three 60 min sessions weekly
Trial: 17641452
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (43 overweight or obese boys) with only two curricular physical education classes weekly
Trial: 15365965
Drug: Low-dose intraperitoneal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intraperitoneal immunoglobulin (IgG) 2 mL (320 mg) with every exchange
Trial: 15365965
Drug: Empiric antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotic treatment (2-week IP ampicillin+sulbactam/netilmycin combination)
Trial: 11231701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.2 mg/d
Trial: 11231701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.4 mg/d
Trial: 11231701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.6 mg/d
Trial: 11231701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.8 mg/d
Trial: 11231701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 1.0 mg/d
Trial: 8349067
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg/d)
Trial: 3768492
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of trimazosin
Trial: 3768492
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of trimazosin
Trial: 28988765
Drug: UroRCC multi-peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UroRCC multi-peptide vaccine
Trial: 30355323
Drug: Autologous adipose
RxNorm normalized name: Autologous adipose derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous adipose tissue injection
Trial: 23020132
Drug: Dabrafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (150 mg) plus trametinib (2 mg)
Trial: 19996977
Drug: 10-day oral
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day oral quadruple therapy regimen with omeprazole (20 mg, twice daily), tetracycline (750 mg, three times daily), metronidazole (500 mg, three times daily), and bismuth potassium citrate (300 mg, twice daily)
Trial: 18751503
Drug: Clindamycin 75
RxNorm normalized name: clindamycin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 75 mg capsule (test 1)
Trial: 15701488
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) starting on postoperative day 3
Trial: 10619544
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of electric shocks
Trial: 1820293
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg captopril t.i.d.
Trial: 1820293
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg frusemide or placebo
Trial: 31755915
Drug: Pembrolizumab (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (up to 2 doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities)
Trial: 25618968
Drug: Danzhixiaoyao pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danzhixiaoyao pill (DZXYP)
Trial: 22738907
Drug: Waitlist control/delayed‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control/delayed‐treatment condition
Trial: 18395716
Drug: Coenzyme Q(10),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q(10), 200 mg/day
Trial: 15293818
Drug: TTO-gel (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTO-gel (2.5 per cent)
Trial: 15293818
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) gel (0.2 per cent)